Company Overview and News

 
Calidus Resources bags $10M to accelerate Pilbara Goldfield exploration

2017-09-27 proactiveinvestors.com.au
Calidus Resources Limited (ASX:CAI) has successfully raised $10 million via a share placement to both new and existing institutional and sophisticated investors at an issue price of $0.041 per share.

 
Calidus raises $10m for gold project

2017-09-27 businessnews.com.au
Local gold explorer Calidus Resources has tapped investors for $10 million as it progresses development of its Warrawoona project in the Pilbara.

 
Calidus debuts on ASX

2017-06-22 businessnews.com.au
Gold-focused Calidus Resources has begun trading on the ASX after raising $7.8 million from investors and completing a reverse takeover of biotech company Pharmanet Group.

 
ASX Capital Raising Complete

2017-06-05 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company is pleased to announce that it has today received notice that Pharmanet Group Limited, to be renamed Calidus Resources Limited, has been notified that all funds have been received pursuant to the ASX Capital Raising as previously announced. These funds total A$7,875,000 (£4.5million).

 
Conditional Approval for Calidus Resources Listing

2017-06-01 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company is pleased to advise that the ASX has today given conditional approval for the shares of Pharmanet Group Limited ("Pharmanet"), to be reinstated to trading on the ASX.  As previously announced, upon restoration, Pharmanet will be renamed Calidus Resources Limited ("Calidus").

 
Approval for Pharmanet Group to acquire Keras Gold

2017-05-30 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company is pleased to advise that shareholders of Pharmanet Group Limited ("Pharmanet") have approved all the resolutions associated with the acquisition of 100% of the issued share capital of the Company's wholly owned subsidiary Keras (Gold) Australia Pty Ltd ("Keras Australia") at a general meeting of shareholders held today in Perth, Australia.

 
Result of General Meeting

2017-05-24 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company, is pleased to announce that all resolutions were passed at the General Meeting of the Company held earlier today.

 
Interim Results

2017-05-22 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company, is pleased to announce its interim results for the six months ended 31 March 2017.

 
Lodged Prospectus for ASX Listing

2017-05-08 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company, is pleased to confirm that ASX quoted Pharmanet Group Limited ("Pharmanet") lodged a prospectus with the Australian Securities and Investments Commission (the "Prospectus") on 5 May 2017.  The Prospectus has been lodged in order to raise A$7.8 million (approximately £4.6 million) (the "ASX Capital Raising") as part of the proposed acquisition by Pharmanet of 100% of the issued share capital of the Company's wholly owned subsidiary Keras (Gold) Australia Pty Ltd ("Keras Australia") as previously announced on 21 March 2017 (the "Transaction").

 
Notice of General Meeting & Corporate Update

2017-04-28 londonstockexchange
Keras Resources plc, the AIM listed mineral resource company, announces that a circular and Notice of General Meeting will be posted to shareholders on 2 May 2017 ("the Circular") relating to the proposed acquisition by Pharmanet Group Limited ("Pharmanet") of 100% of the issued share capital of the Company's wholly owned subsidiary Keras (Gold) Australia Pty Ltd ("Keras Australia") as previously announced on 21 March 2017 (the "Transaction").

 
?530,000 Placing & appointment of Joint Brokers

2017-04-24 londonstockexchange
Keras Resources plc is pleased to announce that it has raised £530,000 (before expenses) from new and existing shareholders through the placing of 151,428,560 ordinary shares of 0.1p each ('Ordinary Shares') at a placing price of 0.35p per Ordinary Share (the 'Placing Shares') and the grant of 75,714,280 warrants to subscribe for new Ordinary Shares (the 'Placing Warrants') (together the 'Placing').

 
Oversubscribed Placing to Support ASX Listing

2017-04-18 londonstockexchange
Keras Resources plc is pleased to announce that Pharmanet Group Limited ("Pharmanet") (ASX: PNO), the ASX listed company which the Company will reverse its wholly owned gold subsidiary, Keras (Gold) Australia Pty Ltd ("Keras Australia") into, has successfully raised A$620,000 (before expenses) from sophisticated investors in Australia (the "Placing").  

 
Pharmanet to relist as gold company

2017-03-22 businessnews.com.au
Dormant Perth-based biotech company Pharmanet Group will re-emerge as a gold explorer after entering into an agreement to acquire Keras Australia by way of a reverse takeover.

 
Shareholder and Analyst Conference Call

2017-03-21 londonstockexchange
Keras Resources plc is pleased to announce that it will be holding a shareholder and analyst conference call on Wednesday 22 March 2017 at 10.30 am GMT.  During the call, Managing Director, Dave Reeves will be discussing the proposed listing of the Company's gold assets on the Australian Stock Exchange via the transaction under which Keras (Gold) Australia Pty Ltd ("Keras Australia") will be sold to  Pharmanet Group Limited ("Pharmanet") by an exchange of shares, which was announced earlier today (the "Transaction").

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...